Photo: Terry Vine / DigitalVision / Getty Images
The FDA is approving another injectable weight loss drug from Eli Lilly.
The drug Mounjaro is approved to treat diabetes and now a variation approved for weight loss will be called Zepbound.
The FDA approved the drug for those with a BMI over 30 characterized as overweight with at least one health condition related to their weight.
Zepbound, generically called tirzepatide, helps suppress appetite to reduce food intake, and is injected once weekly, according to the FDA.
In clinical trials tirzepatide helped people lose an average of 52 pounds for subjects with a median weight of 231 pounds, in 72 weeks.
Zepbound is expected to be available in six dosage strengths by the end of December.
appetite to reduce food intake, and is injected once weekly, according to the FDA.